Pictet Asset Management (UK)’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Pictet Asset Management (UK)’s Portfolio GEVA Stock Details GEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-60,475	Closed	-$5.56M	–	920
2015 Q1	$5.56M	Sell	60,475 -36,018	-37%	-$3.81M	0.02%	566
2014 Q4	$8.95M	Buy	96,493 +56,093	+139%	+$4.43M	0.04%	435
2014 Q3	$2.78M	Sell	40,400 -78,800	-66%	-$5.64M	0.01%	687
2014 Q2	$12.5M	Buy	119,200 +26,600	+29%	+$2.26M	0.06%	339
2014 Q1	$7.68M	Sell	92,600 -5,100	-5%	-$472K	0.04%	428
2013 Q4	$6.32M	Sell	97,700 -4,600	-4%	-$273K	0.03%	455
2013 Q3	$6.48M	Sell	102,300 -52,700	-34%	-$2.59M	0.04%	447
2013 Q2	$6.51M	Buy	+155,000	New	+$7.06M	0.04%	420

Pictet Asset Management (UK)'s GEVA Position: Q2 2015 in Review

Pictet Asset Management (UK) sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 60,475 shares — an estimated $5.56M sold.

Pictet Asset Management (UK) first reported a position in GEVA in Q2 2013 and held it in 8 quarters. The position peaked at $12.5M in Q2 2014. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

Pictet Asset Management (UK) reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
Pictet Asset Management (UK) sold 60,475 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $5.56M.
Pictet Asset Management (UK) first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 8 quarters.
Pictet Asset Management (UK)'s SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $12.5M in Q2 2014.
0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on Pictet Asset Management (UK)'s 13F filing for Q2 2015, filed 13 Aug 2015.